Cancer Letters
Volume 228, Issue 1 , Pages 21-27 , 18 October 2005

MDM2 as MYCN transcriptional target: Implications for neuroblastoma pathogenesis

  • Andrew Slack

      Affiliations

    • Department of Pediatrics, Texas Children's Cancer Center and Center for Cell and Gene Therapy, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA
    • ,
  • Guillermina Lozano

      Affiliations

    • Department of Molecular Genetics, Section of Cancer Genetics, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USA
    • ,
  • Jason M. Shohet

      Affiliations

    • Department of Pediatrics, Texas Children's Cancer Center and Center for Cell and Gene Therapy, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA
    • Corresponding Author InformationCorresponding author. Tel.: +31 20 5666592.

Received 15 December 2004 ,Accepted 12 January 2005.

References 

  1. Schwab M. MYCN in neuronal tumours. Cancer Lett. 2004;204:179–187
  2. Weiss WA, Aldape K, Mohapatra G, Feuerstein GBG, Bishop JM. Targeted expression of MYCN causes neuroblastoma in transgenic mice. Embo J. 1997;16:2985–2995
  3. Nesbit CE, Tersak JM, Prochownik EV. MYC oncogenes human neoplastic disease. Oncogene. 1999;18:3004–3016
  4. Felsher DW, Bishop JM. Transient excess of MYC activity can elicit genomic instability and tumorigenesis. Proc. Natl. Acad. Sci. USA. 1999;96:3940–3944
  5. Lutz W, Stohr M, Schurmann J, Wenzel A, Lohr A, Schwab M. Conditional expression of N-myc in human neuroblastoma cells increases expression of alpha-prothymosin and ornithine decarboxylase and accelerates progression into S-phase early after mitogenic stimulation of quiescent cells. Oncogene. 1996;13:803–812
  6. Fotsis T, Breit S, Lutz W, Rossler J, Hatzi E, Schwab M, et al. Down-regulation of endothelial cell growth inhibitors by enhanced MYCN oncogene expression in human neuroblastoma cells. Eur. J. Biochem. 1999;263:757–764
  7. Schweigerer L, Breit S, Wenzel A, Tsunamoto K, Ludwig R, Schwab M. Augmented MYCN expression advances the malignant phenotype of human neuroblastoma cells: evidence for induction of autocrine growth factor activity. Cancer Res. 1990;50:4411–4416
  8. van Noesel MM, Versteeg R. Pediatric neuroblastomas: genetic and epigenetic danse macabre. Gene. 2004;325:1–15
  9. Nilsson JA, Cleveland JL. Myc pathways provoking cell suicide and cancer. Oncogene. 2003;22:9007–9021
  10. Hogarty MD. The requirement for evasion of programmed cell death in neuroblastomas with MYCN amplification. Cancer Lett. 2003;197:173–179
  11. Weinmann AS, Farnham PJ. Identification of unknown target genes of human transcription factors using chromatin immunoprecipitation. Methods. 2002;26:37–47
  12. Slack A, Chen Z, Tonelli R, Pule M, Hunt L, Pession A, et al. The p53 regulatory gene MDM2 is a direct transcriptional target of MYCN in neuroblastoma. Proc. Natl. Acad. Sci. USA. 2005;102(3):731–736
  13. Hosoi G, Hara J, Okamura T, Osugi S, Ishihara M, Fukuzawa A, et al. Low frequency of the p53 gene mutations in neuroblastoma. Cancer. 1994;73:3087–3093
  14. Vogan K, Bernstein M, Leclerc JM, Brisson L, Brossard J, Brodeur GM, et al. Absence of p53 gene mutations in primary neuroblastomas. Cancer Res. 1993;53:5269–5273
  15. Fakharzadeh SS, Trusko SP, George DL. Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line. Embo J. 1991;10:1565–1569
  16. Finlay CA. The mdm-2 oncogene can overcome wild-type p53 suppression of transformed cell growth. Mol. Cell Biol. 1993;13:301–306
  17. Ganguli G, Wasylyk B. p53-independent functions of MDM2. Mol. Cancer Res. 2003;1:1027–1035
  18. Reifenberger G, Liu L, Ichimura K, Schmidt EE, Collins VP. Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations. Cancer Res. 1993;53:2736–2739
  19. Leach FS, Tokino T, Meltzer P, Burrell M, Oliner JD, Smith S, et al. p53 mutation and MDM2 amplification in human soft tissue sarcomas. Cancer Res. 1993;53:2231–2234
  20. Cordon-Cardo C, Latres E, Drobnjak Mr, Oliva D, Pollack JM, et al. Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas. Cancer Res. 1994;54:794–799
  21. Wurl P, Meye A, Schmidt H, Lautenschlager C, Kalthoff H, Rath FW, et al. High prognostic significance of Mdm2/p53 co-overexpression in soft tissue sarcomas of the extremities. Oncogene. 1998;16:1183–1185
  22. Moller MB, Nielsen O, Pedersen NT. Oncoprotein MDM2 overexpression is associated with poor prognosis in distinct non-Hodgkin's lymphoma entities. Mod. Pathol. 1999;12:1010–1016
  23. Pagnano KB, Vassallo J, Lorand-Metze I, Cosat FF, Saad ST. p53, Mdm2, and c-Myc overexpression is associated with a poor prognosis in aggressive non-Hodgkin's lymphomas. Am. J. Hematol. 2001;67:84–92
  24. Finnegan MC, Goepel JR, Royds J, Hancock BW, Goyns MH. Elevated levels of MDM-2 and p53 expression are associated with high grade non-Hodgkin's lymphomas. Cancer Lett. 1994;86:215–221
  25. Oren M. Decision making by p53: life, death and cancer. Cell Death Differ. 2003;10:431–442
  26. Deb SP. Cell cycle regulatory functions of the human oncoprotein MDM2. Mol. Cancer Res. 2003;1:1009–1016
  27. Momand J, Zambetti GP, Olson DC, George D, Levine AJ. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell. 1992;69:1237–1245
  28. Roth J, Dobbelstein M, Freedman DA, Shenk T, Levine AJ. Nucleo-cytoplasmic shuttling of the hdm2 oncoprotein regulates the levels of the p53 protein via a pathway used by the human immunodeficiency virus rev protein. Embo J. 1998;17:554–564
  29. Freedman DA, Levine AJ. Nuclear export is required for degradation of endogenous p53 by MDM2 and human papillomavirus E6. Mol. Cell Biol. 1998;18:7288–7293
  30. Kubbutat MH, Jones SN, Vousden KH. Regulation of p53 stability by Mdm2. Nature. 1997;387:299–303
  31. Honda R, Tanaka H, Yasuda H. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. Fed. Eur. Biochem. Soc. Lett. 1997;420:25–27
  32. Haupt Y, Maya R, Kazaz A, Oren M. Mdm2 promotes the rapid degradation of p53. Nature. 1997;387:296–299
  33. Jin Y, Lee H, Zeng SX, Dai MS, Lu H. MDM2 promotes p21waf1/cip1 proteasomal turnover independently of ubiquitylation. Eur. Mol. Biol. Org J. 2003;22:6365–6377
  34. Martin K, Trouche D, Hagemeier C, Sorensen TS, LaThangue NB, Kouzarides T. Stimulation of E2F1/DP1 transcriptional activity by MDM2 oncoprotein. Nature. 1995;375:691–694
  35. Xiao ZX, Chen J, Levine AJ, Modjtahedi N, Xing J, Sellers WR, et al. Interaction between the retinoblastoma protein and the oncoprotein MDM2. Nature. 1995;375:694–698
  36. Kobet E, Zeng X, Zhu Y, Keller D, Lu H. MDM2 inhibits p300-mediated p53 acetylation and activation by forming a ternary complex with the two proteins. Proc. Natl. Acad. Sci. U.S.A. 2000;97:12547–12552
  37. Lundgren K, Montes de Oca Luna R, McNeill YB, Emerick EP, Spencer B, Barfield CR, et al. Targeted expression of MDM2 uncouples S phase from mitosis and inhibits mammary gland development independent of p53. Genes Dev. 1997;11:714–725
  38. Komuro H, Hayashi Y, Kawamura M, Hayashi K, Kaneko Y, Kamoshita S, et al. Mutations of the p53 gene are involved in Ewing's sarcomas but not in neuroblastomas. Cancer Res. 1993;53:5284–5288
  39. Goldman SC, Chen CY, Lansing TJ, Gilmer TM, Kastan MB. The p53 signal transduction pathway is intact in human neuroblastoma despite cytoplasmic localization. Am. J. Pathol. 1996;148:1381–1385
  40. Tweddle DA, Malcolm AJ, Cole M, Pearson AD, Lunec J. p53 cellular localization and function in neuroblastoma: evidence for defective G(1) arrest despite WAF1 induction in MYCN-amplified cells. Am. J. Pathol. 2001;158:2067–2077
  41. McKenzie PP, Guichard SM, Middlemas DS, Ashmun RA, Danks MK, Harris LC. Wild-type p53 can induce p21 and apoptosis in neuroblastoma cells but the DNA damage-induced G1 checkpoint function is attenuated. Clin. Cancer Res. 1999;5:4199–4207
  42. Rodriguez-Lopez AM, Xenaki D, Eden TO, Hickman JA, Chresta CM. MDM2 mediated nuclear exclusion of p53 attenuates etoposide-induced apoptosis in neuroblastoma cells. Mol. Pharmacol. 2001;59:135–143
  43. Keshelava N, Zuo JJ, Chen P, Waidyaratne SN, Luna MC, Gomer CJ, et al. Loss of p53 function confers high-level multidrug resistance in neuroblastoma cell lines. Cancer Res. 2001;61:6185–6193
  44. Isaacs JS, Saito S, Neckers LM. Requirement for HDM2 activity in the rapid degradation of p53 in neuroblastoma. J. Biol. Chem. 2001;276:18497–18506
  45. Jones SN, Roe AE, Donehower LA, Bradley A. Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53. Nature. 1995;378:206–208
  46. Montes de Oca Luna R, Wagner DS, Lozano G. Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature. 1995;378:203–206
  47. Chavez-Reyes A, Parant JM, Amelse LL, Montes de Oca Luna R, Korsmeyer SJ, Lozano G. Switching mechanisms of cell death in mdm2- and mdm4-null mice by deletion of p53 downstream targets. Cancer Res. 2003;63:8664–8669
  48. McDonnell TJ, Montes de Oca Luna R, Cho S, Amelse LL, Chavez-Reyes A, Lozano G. Loss of one but not two mdm2 null alleles alters the tumour spectrum in p53 null mice. J. Pathol. 1999;188:322–328
  49. Adams JM, Harris AW, Pinkert CA, Corcoran LM, Alexander WS, Cory S, et al. The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature. 1985;318:533–538
  50. Alt JR, Greiner TC, Cleveland JL, Eischen CM. Mdm2 haplo-insufficiency profoundly inhibits Myc-induced lymphomagenesis. Eur. Mol. Biol. Org J. 2003;22:1442–1450
  51. Bond GL, Hu W, Bond EE, Robins H, Lutzker SG, Arva NC, et al. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell. 2004;119:591–602
  52. Lutz W, Fulda S, Jeremias I, Debatin KM, Schwab M. MYCN and IFNgamma cooperate in apoptosis of human neuroblastoma cells. Oncogene. 1998;17:339–346
  53. Teitz T, Wei T, Valentine MB, Vanin EF, Grenet J, Valentine VA, et al. Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN. Nat. Med. 2000;6:529–535
  54. Takita J, Yang HW, Bessho F, Hanada R, Yamamoto K, Kidd V, et al. Absent or reduced expression of the caspase 8 gene occurs frequently in neuroblastoma, but not commonly in Ewing sarcoma or rhabdomyosarcoma. Med. Pediatr. Oncol. 2000;35:541–543
  55. Castle VP, Heidelberger KP, Bromberg J, Ou X, Dole M, Nunez G. Expression of the apoptosis-suppressing protein bcl-2, in neuroblastoma is associated with unfavorable histology and N-myc amplification, Am. J. Pathol. 1993;143:1543–1550
  56. Adida C, Berrebi D, Peuchmaur M, Reyes-Mugica M, Altieri DC. Anti-apoptosis gene, surviving, and prognosis of neuroblastoma. Lancet. 1998;351:882–883
  57. Korsmeyer SJ. Bcl-2 initiates a new category of oncogenes: regulators of cell death. Blood. 1992;80:879–886
  58. Zindy F, Eischen CM, Randle DH, Kamijo T, Cleveland JL, Sherr CJ, et al. Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. Genes Dev. 1998;12:2424–2433
  59. Kamijo T, Zindy F, Roussel MF, Quelle DE, Downing JR, Ashmun RA, et al. Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF. Cell. 1997;91:649–659
  60. Pomerantz J, Schreiber-Agus N, Liegeois NJ, Silverman A, Alland L, Chin L, et al. The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell. 1998;92:713–723
  61. Hansford LM, Thomas WD, Keating JM, Burkhart CA, Peaston AE, Norris MD, et al. Mechanisms of embryonal tumor initiation: distinct roles for MYCN expression and MYCN amplification. Proc. Natl. Acad. Sci. USA. 2004;101:12664–12669
  62. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science. 2004;303:844–848
  63. Zhang Z, Li M, Wang H, Agrawal S, Zhang R. Antisense therapy targeting MDM2 oncogene in prostate cancer: Effects on proliferation, apoptosis, multiple gene expression, and chemotherapy. Proc. Natl. Acad. Sci. USA. 2003;100:11636–11641
  64. Zhang Z, Wang H, Prasad G, Li M, Yu D, Bonner JA, et al. Radiosensitization by antisense anti-MDM2 mixed-backbone oligonucleotide in in vitro and in vivo human cancer models. Clin. Cancer Res. 2004;10:1263–1273

PII: S0304-3835(05)00350-2

doi: 10.1016/j.canlet.2005.01.050

Cancer Letters
Volume 228, Issue 1 , Pages 21-27 , 18 October 2005

Article Tools

* Image Usage & Resolution